Highlights

  • Biome Australia shares rose 6.67% on 2 February, outperforming a declining ASX 200 index.
  • The company announced a new Canadian distribution partnership with Fullscript.
  • The healthcare index ended the session lower, underscoring the stock’s relative performance.

Shares of Biome Australia Ltd (ASX:BIO) moved higher on Monday, outperforming the broader market and the healthcare sector, after the company announced an expansion of its Canadian practitioner distribution network. The stock gained more than 6% during the session, even as the benchmark S&P/ASX 200 and the ASX healthcare index closed lower.

Biome Australia Shares Advance as Market Declines

Biome Australia closed at AUD 0.48 on 2 February, up 6.67% for the day. The move came against a weaker broader market backdrop, with the S&P/ASX 200 index falling 1.02 percent to 8,778.60 points. The ASX healthcare index also ended lower, declining around 0.79 percent during the session.

Despite the broader weakness, Biome’s share price performance stood out. Over the past month, the stock has gained 14.29%, although it remains down 15.79% over the past year.

Canadian Expansion Announcement Lifts Investor Attention

The stock movement followed an ASX announcement released earlier in the day, in which Biome confirmed it had secured distribution of its full Activated Probiotics range on Fullscript Canada. The platform serves more than 100,000 healthcare practitioners and approximately 5 million patients across North America, with the product launch scheduled for February 2026.

Under the agreement, all Biome Activated Probiotics products have been approved for launch on the Fullscript Canada platform. The partnership adds a digital practitioner-to-patient channel to Biome’s existing Canadian distribution network.

Full Market Coverage Through Dual-Channel Model

The Fullscript partnership complements Biome’s existing relationship with Ecotrend Ecologics, a Canadian natural health products distributor with over three decades of industry presence. Together, the two arrangements provide coverage across both traditional wholesale distribution and digital direct-to-patient dispensing models.

This structure enables practitioners to access Biome products either through in-clinic inventory ordering or via Fullscript’s e-prescribing system, which ships products directly to patients’ homes. Canada’s practitioner channel is largely driven by naturopathic doctors operating under a regulated framework for natural health products.

Company Background and International Footprint

Biome Australia develops and commercialises evidence-based probiotics and complementary medicines supported by clinical research. The company operates across practitioner-led distribution channels in Australia and international markets, including Canada, Ireland, New Zealand, and the United Kingdom.

The company’s Activated Probiotics range is supported by clinical trials and is used across multiple health categories, including digestive health, sleep, mood, and immune support. Biome stated that the Fullscript agreement forms part of its longer-term international expansion plans.